Lexicon Pharmaceuticals (LXRX) reported second-quarter 2026 total revenue of $0.7 million, down from $28.9 million a year earlier, and a net loss of $31.8 million, or $0.07 per share. The company said revenue consisted of net sales of INPEFA.
The company also said enrollment is complete in its Phase 3 SONATA-HCM study, with topline results expected in the first quarter of 2027. Lexicon said activities to resubmit the ZYNQUISTA NDA in type 1 diabetes are nearing completion, and Phase 1 development of LX9851 is ongoing by Novo Nordisk.
- Total revenues were $0.7 million for Q2 2026, compared with $28.9 million in Q2 2025.
- Net loss was $31.8 million, compared with net income of $3.3 million in the year-earlier period.
- Cash and investments were $190.6 million as of June 30, 2026.
- Lexicon completed enrollment in SONATA-HCM and continues to expect topline data in Q1 2027.
- The company entered into a $100 million loan facility with Hercules Capital in May 2026.
$LXRX Insider Trading Activity
$LXRX insiders have traded $LXRX stock on the open market 4 times in the past 6 months. Of those trades, 4 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $LXRX stock by insiders over the last 6 months:
- RAYMOND DEBBANE has made 4 purchases buying 252,000 shares for an estimated $369,735 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$LXRX Hedge Fund Activity
We have seen 64 institutional investors add shares of $LXRX stock to their portfolio, and 46 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ARTAL GROUP S.A. added 18,553,846 shares (+13.6%) to their portfolio in Q1 2026, for an estimated $28,943,999
- SESSA CAPITAL IM, L.P. added 14,912,961 shares (+497.1%) to their portfolio in Q1 2026, for an estimated $23,264,219
- POINT72 ASSET MANAGEMENT, L.P. added 7,530,581 shares (+2651.4%) to their portfolio in Q1 2026, for an estimated $11,747,706
- FMR LLC added 7,222,131 shares (+19.1%) to their portfolio in Q1 2026, for an estimated $11,266,524
- SIREN, L.L.C. added 5,384,615 shares (+13.8%) to their portfolio in Q1 2026, for an estimated $8,399,999
- RENAISSANCE TECHNOLOGIES LLC added 1,337,246 shares (+508.0%) to their portfolio in Q1 2026, for an estimated $2,086,103
- MARSHALL WACE, LLP added 1,113,937 shares (+88.2%) to their portfolio in Q1 2026, for an estimated $1,737,741
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
